Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities
Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating for Fate Therapeutics with a $2.00 price target. The stock closed at $0.96. Ahmad, a 3-star analyst, has a 1.8% average return and a 54.71% success rate. Fate Therapeutics also received a Hold from Needham's Gil Blum, while H.C. Wainwright upgraded it to Buy on October 31.
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on Fate Therapeutics, with a price target of $2.00. The company’s shares closed yesterday at $0.96.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Ahmad is a 3-star analyst with an average return of 1.8% and a 54.71% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Incyte, and BioNTech SE.
In addition to Bank of America Securities, Fate Therapeutics also received a Hold from Needham’s Gil Blum in a report issued on November 13. However, on October 31, H.C. Wainwright upgraded Fate Therapeutics (NASDAQ: FATE) to a Buy.
